✦ LIBER ✦

150 INVITED Trial design issues in advanced pancreatic cancer

✍ Scribed by B. Glimelius

Book ID: 118625107
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 79 KB
Volume: 5
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(07)70264-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

152 INVITED Biological agents in advance

152 INVITED Biological agents in advanced pancreatic cancer

✍ M. Moore 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 59 KB

Regional Chemotherapy in Locally Advance

Regional Chemotherapy in Locally Advanced Pancreatic Cancer: RECLAP Trial

✍ Jeremy L Davis; Prakash Pandalai; R Taylor Ripley; Russell C Langan; Seth M Stei 📂 Article 📅 2011 🏛 BioMed Central 🌐 English ⚖ 308 KB

151 INVITED Single agent versus combinat

151 INVITED Single agent versus combination of drugs in advanced pancreatic cancer

✍ C. Louvet 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 59 KB

Phase II Trial of Curcumin in Patients w

Phase II Trial of Curcumin in Patients with Advanced Pancreatic Cancer

✍ Dhillon, N.; Aggarwal, B. B.; Newman, R. A.; Wolff, R. A.; Kunnumakkara, A. B.; 📂 Article 📅 2008 🏛 American Association for Cancer Research 🌐 English ⚖ 661 KB

A phase II trial of FUdR in patients wit

A phase II trial of FUdR in patients with advanced pancreatic cancer

✍ Bach Ardalan; Mayra Lima 📂 Article 📅 2004 🏛 Springer-Verlag 🌐 English ⚖ 185 KB

Gemcitabine plus celecoxib (GECO) in adv

Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: a phase II trial

✍ Vittorio Ferrari; Francesca Valcamonico; Vito Amoroso; Edda Simoncini; Lucia Vas 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 200 KB